Thymosin Alpha-1

Thymosin α-1 is a 28-amino-acid acetylated peptide originally isolated from thymic tissue and synthesized as a synthetic identical sequence (thymalfasin) for clinical research. The peptide is a fragment of prothymosin α and is recognized as a thymus-derived immune-modulating compound.

Mechanism of action centers on Toll-like receptor 9 (TLR9) and MyD88-dependent signaling in dendritic cells, with downstream effects on Th1 differentiation, natural killer cell cytotoxicity, and CD8+ T cell response. The peptide enhances dendritic cell maturation and antigen presentation, supporting cell-mediated immunity in immunosuppressed states.

Thymosin α-1 holds regulatory approval in over 30 countries (notably for hepatitis B), and the clinical trial record includes oncology adjuvant settings, viral infection, and sepsis.

Research Applications

• Immune modulation research in immunosuppressed and aging models.
• Adjuvant research in viral infection (hepatitis B, COVID-19) and oncology.
• TLR9 / dendritic cell pharmacology research.
• Geroscience research on thymic involution and immunosenescence.